@thedebway's 'food noise' claim about Wegovy vs Mounjaro

What does this video actually claim?

@thedebway says her "food noise" returned after switching from Mounjaro (tirzepatide) to Wegovy (semaglutide), suggesting Mounjaro worked better for controlling food cravings. She's describing the mental chatter about food that many people experience when not on GLP-1 medications.

The video implies tirzepatide might be more effective than semaglutide for appetite suppression. This is actually a pretty common experience that matches what we're seeing in head-to-head studies.

Does the science back this up?

Yes, and the data is quite clear about this. The SURPASS-2 trial (Frías et al., NEJM, 2021) directly compared 15mg tirzepatide to 1mg semaglutide in people with type 2 diabetes. Tirzepatide led to 11.2kg weight loss versus 5.7kg with semaglutide at 40 weeks.

The mechanism explains why. Tirzepatide targets both GLP-1 and GIP receptors, while semaglutide only hits GLP-1. GIP affects insulin sensitivity and may have additional appetite effects through different brain pathways.

@thedebway's experience matches what we'd expect based on the dual receptor action.

What's missing from her account?

She doesn't mention doses, which matters enormously here. The SURPASS-2 trial used 1mg semaglutide, but Wegovy goes up to 2.4mg. At maximum doses, the gap narrows considerably, though tirzepatide still appears superior.

The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed 15mg tirzepatide achieved 20.9% weight loss at 72 weeks. The STEP 1 trial with 2.4mg semaglutide hit 14.9% at 68 weeks. Still a meaningful difference, but not as dramatic as lower-dose comparisons suggest.

Why might someone experience this switch?

Insurance coverage often forces these medication switches, and the transition isn't always smooth. Different GLP-1 drugs have varying half-lives and receptor binding patterns. Semaglutide has a 7-day half-life, while tirzepatide lasts about 5 days.

Some people do better on one versus the other, even at equivalent doses. The dual incretin approach of tirzepatide seems to provide more consistent appetite suppression for many patients, though individual responses vary significantly.

What should you actually know?

@thedebway's experience reflects real pharmacological differences between these medications. Tirzepatide does appear more effective for weight loss and appetite control in most people, based on current trial data.

But medication switches should involve dose optimization and timing considerations. If you're switching from tirzepatide to semaglutide, you'll likely need the full 2.4mg dose to get comparable effects. Don't assume the drugs are interchangeable at any dose level.